More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Orantinib [252916-29-3]
Chemical Structure
Chemical Structure
Chemical Structure

Orantinib [252916-29-3]

Research Use Only
CDX-O0202
Chemodex
CAS Number252916-29-3
DownloadDatasheet
Product group Chemicals
Estimated Purity>98%
Molecular Weight310.35
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    Chemodex
  • Product Name
    Orantinib [252916-29-3]
  • Delivery Days Customer
    10
  • CAS Number
    252916-29-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C18H18N2O3
  • Molecular Weight
    310.35
  • Scientific Description
    Chemical. CAS: 252916-29-3. Formula: C18H18N2O3. MW: 310.35. Orantinib is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. It is a potent ATP-competitive inhibitor of PDGFRbeta, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 microM, respectively) but not EGFR (IC50 >100 microM). Orantinib suppresses tumor growth, blocks angiogenesis in tumors and induces apoptosis of tumor vasculature and regression of established tumors. Orantinib inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells, inhibits Aurora kinases B and C (IC50=35 and 210nM, respectively), and inhibits Unc-51-like serine/threonine kinase Ulk3, involved in hedgehog signaling. All together ornatinib exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity. - Orantinib is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. It is a potent ATP-competitive inhibitor of PDGFRbeta, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 microM, respectively) but not EGFR (IC50 >100 microM). Orantinib suppresses tumor growth, blocks angiogenesis in tumors and induces apoptosis of tumor vasculature and regression of established tumors. Orantinib inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells, inhibits Aurora kinases B and C (IC50=35 and 210nM, respectively), and inhibits Unc-51-like serine/threonine kinase Ulk3, involved in hedgehog signaling. All together ornatinib exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity.
  • SMILES
    O=C1NC2=CC=CC=C2/C1=C/C3=C(C)C(CCC(O)=O)=C(C)N3
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200